Bayer, Loxo enter $1.6B cancer deal

Loxo Oncology Inc. (NASDAQ:LOXO) and Bayer AG (Xetra:BAYN) partnered on Nov. 14 to develop and commercialize larotrectinib (LOXO-101) and LOXO-195 worldwide. Loxo will receive $400 million up front, and is eligible for $1.2 billion

Read the full 346 word article

User Sign In